secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001437749-25-020973
Event type: debt
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu expands debt facility to $13M term loan plus $1.5M revolver; maturity extended to June 2029 for EXXUA launch
--------------------------------------------------------------------------------

- Term loan principal increased to $13.0M from $11.1M; maturity extended to June 12, 2029.
- Revolving credit facility expanded by $1.5M incremental advance at SOFR+5.5%, repayable $125K/month starting August 1, 2025.
- Provides working capital flexibility as Aytu prepares for commercial launch of EXXUA (gepirone) for MDD expected Q4 2025.
- Follows earlier $16.6M public offering closed earlier in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/0001437749-25-020973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774925020973/aytu20250611_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-020973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer